Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 18, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership...
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with...
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 09, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
May 05, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
May 03, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
April 25, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six...
First AI-Powered ALS Educational Platform Launches for the Public
April 20, 2022 11:30 ET
|
StoryFile
Los Angeles, CA, April 20, 2022 (GLOBE NEWSWIRE) -- StoryFile, an AI startup redefining the media landscape through its proprietary storytelling technology, announced the launch of its first...
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
April 18, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
April 14, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
April 04, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to...